Campbell DJ, et al. - In a community-based population at increased risk for cardiovascular disease (CVD), researchers investigated serum amino-terminal pro-B-type-natriuretic peptide (NT-proBNP) levels that could inform heart failure (HF) risk. Study participants included those who were aged ≥ 60 years with ≥ 1 of: self-reported hypertension, diabetes, heart disease, abnormal heart rhythm, cerebrovascular disease, or renal impairment. Those with known HF, ejection fraction (EF) < 50%, or more than mild valve abnormality were excluded from the study. Five-year prediction of total HF was enabled by NT-proBNP cut-points of 11, 16, and 25 pmol/L for men and women aged 60–69, 70–79, and ≥ 80 years, respectively, with sensitivities > 76% and specificities of 47% to 69%. The prognostic significance of age-specific serum NT-proBNP levels was evident with respect to HF risk in individuals at increased CVD risk.